

---

**GOVERNMENT NOTICES • GOEWERMENTSKENNISGEWINGS**

---

**DEPARTMENT OF HEALTH****NO. R. 1098****12 OCTOBER 2018****MEDICINES AND RELATED SUBSTANCES ACT, 1965 (ACT No. 101 OF 1965)  
SCHEDULES**

The Minister of Health has, in terms of section 22A(2) of the Medicines and Related Substances Act, 1965 (Act No. 101 of 1965), on the recommendation of the Medicines Control Council, made and updated the Schedules in the Schedule.

This Schedule amends the Schedules as inserted by Government Notice R.509 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 24727, 10 April 2003; substituted by Government Notice R.935 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 31387, 5 September 2008; and amended by Government Notice R.1230 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 32838, 31 December 2009; Government Notice R.227 (Medicines and Related Substances Act: Schedules) in Government *Gazette* 35149, 15 March 2012; Government Notice R.674 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 36827, 13 September 2013, Government Notice R.690 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 36850, 20 September 2013, Government Notice R.104 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 37318, 11 February 2014; Government Notice R.352 (Medicines and Related Substances Act, 1965: Schedules) in, Government *Gazette* 37622, 8 May 2014; Government Notice R.234 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 38586, 20 March 2015; Government Notice R.254 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 39815, 15 March 2016; Government Notice R.254 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 40041, 03 June 2016; Government Notice No.748 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 41009, 28 July 2017; and Government Notice No.1261 (Medicines and Related Substances Act, 1965: Schedules) in Government *Gazette* 41256, 17 November 2017 using the following convention:

- Words in bold and in square brackets (e.g. **[Gamma benzene hexachloride]** in Schedule 1), indicate omission from a Schedule
- Words underlined with a solid line (e.g. Gamma benzene hexachloride), indicate insertions in a Schedule.

## SCHEDULE

In these Schedules, "the Act" means the Medicines and Related Substances Act, 1965 (Act No.101 of 1965)

Note: Where an alternative schedule(s) is included in natural parentheses at any point of an inscription, this is provided to indicate one or more alternative scheduling designation/s. This is for information only and shall not be used in the interpretation of such inscription.

### SCHEDULE 1

- a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for –
  - (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and
  - (ii) analytical laboratory purposes.
- b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and includes the following:
  - (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and
  - (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.
- c. In terms of section 22A(4)(a)(v) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act No. 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Medicines Control Council, to patients under his/her care,

**SCHEDULE 2**

- a. All substances referred to in this Schedule are excluded when specifically packed, labeled, sold and used for –
- (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and
  - (ii) analytical laboratory purposes.
- b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and includes the following:
- (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and
  - (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.
- c. In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within their scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Medicines Control Council, to patients under his/her care, the Schedule 2 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act.
- (i) Annexure 1A: Emergency Care Provider (Paramedic);
  - (ii) Annexure 1B: Emergency Care Provider (Emergency Care Practitioner);
  - (iii) Annexure 2: Dental Therapist;
  - (iv) Annexure 3: Optometrist.

Atovaquone.

- a. when co-formulated with proguanil and intended and labelled for the chemoprophylaxis of malaria in those weighing 11 kilograms or more. (S4)

Dulaglutide.

Ibuprofen,



**SCHEDULE 3**

- a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for –
- (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and
  - (ii) analytical laboratory purposes.
- b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and includes the following:
- (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and
  - (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.
- c. In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Medicines Control Council, to patients under his/her care, the Schedule 3 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act.
- (i) Annexure 1A: Emergency Care Provider (Paramedic);
  - (ii) Annexure 1B: Emergency Care Provider (Emergency Care Practitioner);
  - (iii) Annexure 2: Dental Therapist;
  - (iv) Annexure 3: Optometrist.

## Ibuprofen, except

- a. when contained in preparations intended for application to the skin, containing 5 % m/m or less of ibuprofen; (S0,S1)
- b. when contained in oral medicinal preparations supplied in a solid dose form as divided doses contained in packs not exceeding 24 dosage units or divided doses and containing ibuprofen as the only active therapeutic substance, intended for the treatment of mild to moderate pain or fever of inflammatory origin or for the treatment of post-traumatic conditions in adults and children over

## Schedule 4

**SCHEDULE 4**

- a. All substances referred to in this Schedule are excluded when specifically packed, labelled, sold and used for –
- (i) industrial purposes including the manufacture or compounding of consumer items or products which have no pharmacological action or medicinal purpose; and
  - (ii) analytical laboratory purposes.
- b. All preparations of substances or mixtures of such substances containing or purporting to contain any substance referred to in this Schedule and includes the following:
- (ii) The salts and esters of such substances, where the existence of such salts and esters is possible; and
  - (iii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.
- c. In terms of section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974 (Act 56 of 1974) other than a medical practitioner or dentist may prescribe and supply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Medicines Control Council, to patients under his/her care, the Schedule 4 substances and medicines provided for in the Annexures to this Schedule published in the Gazette in terms of the Act.
- (i) Annexure 1A: Emergency Care Provider (Paramedic);
  - (ii) Annexure 1B: Emergency Care Provider (Emergency Care Practitioner);
  - (iii) Annexure 2: Dental Therapist;
  - (iv) Annexure 3: Optometrist.

**[Atovaquine]** Atovaquone, except

- a. when co-formulated with proguanil and intended and labelled for the chemoprophylaxis of malaria in those weighing 11 kilograms or more. (S2)

Bazedoxifene.

Daratumumab.

Deoxycholic acid.

Dupilumab.Eftrenonacog alfa (Human coagulation Factor IX).Human Plasma Proteins.

## Ibuprofen,

- a. when intended for the treatment of a haemodynamically significant patent ductus arteriosus in infants less than 34 weeks of gestational age;
- b. except when contained in preparations intended for application to the skin; containing 5 % m/m or less of ibuprofen; (S0, S1)
- c. except when contained in oral medicinal preparations supplied in a solid dose form as divided doses contained in packs not exceeding 24 dosage units or divided doses and containing ibuprofen as the only active therapeutic substance, intended for the treatment of mild to moderate pain or fever of inflammatory origin or for the treatment of post-traumatic conditions in adults and children over 12 years of age where the recommended daily dose of ibuprofen in the case of adults does not exceed 1,2 grams and in children 12 years and older does not exceed 20 milligrams per kilogram of body weight; (S1)
- d. except when contained in oral medicinal preparations intended for human use only, in combination with one or more other active therapeutic substances and intended for the treatment of mild to moderate pain or fever of inflammatory origin for a maximum treatment period of 10 days where the recommended daily dose of ibuprofen in the case of adults does not exceed 1,2 grams and in children over the age of 1 year and up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight; (S2)
- e. except when contained in oral medicinal preparations, intended for human use only, as the only active therapeutic substance in oral liquid preparations in packs not exceeding 100 millilitres in volume or in oral solid preparations in packs exceeding 24 dosage units or divided doses, when intended for adults and children over the age of 1 year; for the treatment of mild to moderate pain of inflammatory origin for a maximum treatment period of 10 days, or for the treatment of fever of inflammatory origin or for the treatment of post-traumatic conditions where the recommended daily dose of ibuprofen for adults does not exceed 1,2 grams and for children over the age of 1 year and up to and including the age of 12 years does not exceed 20 milligrams per kilogram of body weight; (S2)
- f. except for the emergency treatment of acute gout attacks for a maximum treatment period of 5 days; (S2)
- g. except when intended for veterinary use. (S3)

Ixazomib.

## Schedule 4

Lubiprostone.

Mepolizumab.

Midostaurin.

Oclacitinib.

Orphenadrine, except when contained in preparations intended for use as a muscle relaxant. (S2)

Proguanil, except

- a. when co-formulated with atovaquone and intended and labelled for the chemoprophylaxis of malaria in those weighing 11 kilograms or more. (S2)

Ramucirumab.

Siltuximab.

Tetanus toxoid.

Tipiracil.

Tofacitinib.

Vedolizumab.

**– END SCHEDULE 4 –**



**SCHEDULE 5 AND SPECIFIED SCHEDULE 5**

- a. All preparations or mixtures of such substances containing or purporting to contain substances that is chemically related and incorporates a structural fragment into its structure that is similar to the structure of a listed substance and /or exhibits pharmacodynamic properties similar to the listed substance referred to in this Schedule include the following:
- (i) The salts and esters of such substances, where the existence of such salts and esters is possible; and
  - (ii) all preparations and mixtures of such substances where such preparations and mixtures are not expressly excluded.
  - (iii) all homologues of listed substances (being any chemically related substances that incorporate a structural fragment into their structures that is similar to the structure of a listed substance and/or exhibit pharmacodynamic properties similar to the listed substance in the schedules), unless listed separately in the Schedules.
- b. In terms of Section 22A(5)(f) of the Act, a practitioner, nurse or a person registered under the Health Professions Act, 1974, other than a medical practitioner or dentist, may prescribe and apply, only within his/her scope of practice and subject to the indication for use of such substances and medicines and to the conditions determined by the Medicines Control Council, to patients under his/her care, the Schedule 5 and Specified Schedule 5 substances and medicines provided for in the Annexures to this Schedule published in the *Gazette* in terms of the Act.
- (i) Annexure 1A: Emergency Care Provider (Paramedic);
  - (ii) Annexure 1B: Emergency Care Provider (Emergency Care Practitioner).
- c. Specified Schedule 5 substances listed in this schedule are subject to additional control in terms of section 22A of the Act as required under the provisions of the 1971 Convention on Psychotropic Substances and are denoted by \*\*



Schedule 5

Brexpiprazole.

– END SCHEDULE 5 –

These Schedules as amended com into operation on the date of publication in the Government Gazette.



DR A MOTSOLEDI, MP  
MINISTER OF HEALTH  
DATE: 27/6/2018